Global Markets Directs, Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2

A mucopolissacaridose tipo II (MPS II) é uma doença genética de amplo espectro clínico, caracterizada por deficiência da enzima iduronato-2- sulfatase. Revisão sistemática avaliou a eficácia e segurança da terapia de reposição enzimática (TRE) com idursulfase (IDS) na MPS II. As bases de dados PubMed/MEDLINE, Embase, LILACS e Biblioteca Cochrane foram pesquisados até 30 de novembro de 2012. Apenas cinco estudos preencheram os critérios de inclusão (ensaios clínicos randomizados - ECRs, ECRs abertos ou séries de caso prospectivas, incluindo cinco ou mais pacientes e avaliando desfechos relevantes). Metanálise foi realizada para capacidade vital forçada (CVF; valores absolutos e em %) e para a distância percorrida no teste da caminhada dos seis minutos, com mudanças significativas em ambas as variáveis; também foi encontrado risco aumentado de reações leves relacionadas à infusão e de desenvolvimento de anticorpos IgG à IDS. Em face dos dados apresentados neste estudo, ...

Iduronate 2-Sulfatase/IDS Proteins available through Novus Biologicals. Browse our Iduronate 2-Sulfatase/IDS Protein catalog backed by our Guarantee+.

There is evidence of a change of ≥1 but ≤2 standard deviations decline from a previous protocol-defined neurodevelopmental assessment. The duration of protocol-defined neurologic involvement is at least 3 months but less than 36 months as documented in the patients medical history.. 4. The patient has received and tolerated a minimum of 6 months of treatment with weekly intravenous idursulfase, and has received 80% of the total planned infusions within that time frame, including having received 100% of the planned infusions within 4 weeks immediately preceding the surgical insertion of the IDDD.. 5. The patient must have sufficient auditory capacity, with or without aids, to complete the required protocol testing, and be compliant with wearing the aid on scheduled testing days.. 6. The patient, patients parent(s), or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board / Independent Ethics Committee-approved informed consent form after all relevant ...

iduronate 2 sulfatase Antibody 17140-1-AP has been identified with ELISA. 17140-1-AP detected band in {{ptg:PositiveWB}} with {{ptg:WesternTiter}} dilution...

It is very important that your doctor check your or your childs progress at regular visits. This will allow your doctor to see if the medicine is working properly and check you for unwanted effects that may be caused by this medicine. This medicine may cause serious allergic reactions, including anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Tell your doctor or nurse right away if you or your child have a rash, itching, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth after you or your child get the injection. ...

The specific binding of Ca(2+) to synthetic hexasaccharide models of modified heparin has been investigated by NMR and molecular modeling and compared with previous results on a model of regular heparin. These two models represent the regular region of heparin lacking one type of O-sulfate group, either at C-6 of glucosamine or at C-2 of iduronate. The NMR experiments show different responses to the presence of Ca(2+). In the case of the compound lacking O-sulfate groups at C-2, the results are indicative of specific binding similar to that observed for the regular heparin, while the model lacking sulfate groups in position 6 interacts more weakly with Ca(2+). In order to understand the basis of this difference, a molecular modeling study based on a rigid body docking approach of the interaction of these carbohydrates with Ca(2+) and Na(+) was performed. We have found that the results are strongly dependent on the starting orientation of the lateral side chains of the charged groups of the ...

Table of contents. 1. Report Introduction. 2. Hunter Syndrome 3. Hunter Syndrome Current Treatment Patterns. 4. Hunter Syndrome - DelveInsights Analytical Perspective. 5. Therapeutic Assessment. 6. Hunter Syndrome Late Stage Products (Phase-III). 7. Hunter Syndrome Mid Stage Products (Phase-II). 8. Early Stage Products (Phase-I). 9. Pre-clinical Products and Discovery Stage Products. 10. Inactive Products. 11. Dormant Products. 12. Hunter Syndrome Discontinued Products. 13. Hunter Syndrome Product Profiles. 14. Hunter Syndrome Key Companies. 15. Hunter Syndrome Key Products. 16. Dormant and Discontinued Products. 17. Hunter Syndrome Unmet Needs. 18. Hunter Syndrome Future Perspectives. 19. Hunter Syndrome Analyst Review 20. Appendix. 21. Report Methodology. About DelveInsight. DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and ...

Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a member of a group of inherited metabolic disorders collectively termed mucopolysaccharidoses (MPSs). The MPSs are caused by a deficiency of lysosomal enzymes required for the degradation of mucopolysaccharides or glycosaminoglycans (GAGs).

Dive into the research topics of Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): Data from the Hunter Outcome Survey. Together they form a unique fingerprint. ...

PubMed journal article [Postnatal and prenatal diagnosis of mucopolysaccharidosis type II (Hunter syndrome) were found in PRIME PubMed. Download Prime PubMed App to iPhone or iPad.

Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. It is a progressively debilitating disorder; however, the rate of progression varies among affected individuals.. At birth, individuals with MPS II do not display any features of the condition. Between ages 2 and 4, they develop full lips, large rounded cheeks, a broad nose, and an enlarged tongue (macroglossia). The vocal cords also enlarge, which results in a deep, hoarse voice. Narrowing of the airway causes frequent upper respiratory infections and short pauses in breathing during sleep (sleep apnea). As the disorder progresses, individuals need medical assistance to keep their airway open.. Many other organs and tissues are affected in MPS II. Individuals with this disorder often have a large head (macrocephaly), a buildup of fluid in the brain (hydrocephalus), an enlarged liver and spleen (hepatosplenomegaly), and a soft ...

Mucopolysaccharidosis type II (MPS II) is an X‐linked lysosomal storage disorder caused by a deficiency of iduronate 2‐sulfatase (IDS)

Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a lysosomal storage disease caused by a deficient (or absent) enzyme, iduronate-2-sulfatase (I2S). The accumulated substrates in Hunter syndrome are heparan sulfate and dermatan sulfate. The syndrome has X-linked recessive inheritance. The symptoms of Hunter syndrome (MPS II) are generally not apparent at birth, but usually start to become noticeable after the first year of life. Often, the first symptoms may include abdominal hernias, ear infections, runny noses, and colds. Since these symptoms are quite common among all infants, they are not likely to lead a doctor to make a diagnosis of Hunter syndrome right away. As the buildup of glycosaminoglycans (GAGs) continues throughout the cells of the body, signs of Hunter syndrome become more visible. Physical appearances of many children with Hunter syndrome include a distinctive coarseness in their facial features, including a prominent forehead, a nose with a flattened bridge, and an ...

With Hunter syndrome, chains of sugar molecules (called mucopolysaccharides) cant be broken down. They accumulate in the body, which harms cells and tissues.. Hunter syndrome, which isnt present at birth, can be either severe or mild. The severe form begins just after age 2, while symptoms of the mild form dont start until later.. Most people with Hunter syndrome will have a larger than normal head; facial features that include a broad nose, flared nostrils, and thickening of the lips, tongue, and nostrils; deafness that worsens over time; joint stiffness; and carpal tunnel syndrome.. The juvenile (severe) form of Hunter syndrome includes aggressive behavior, hyperactivity, severe intellectual disability, and stiff or rigid muscles.. Other signs and symptoms include cardiovascular problems, vision disturbances, enlarged spleen or liver, hernias, and respiratory difficulties.. ...

MPS II is a rare X-linked recessive genetic disease caused by mutations in the iduronate-2-sulfatase (IDS) gene . Enzyme replacement therapy (ERT) with recombinant idursulfase (ELAPRASE®) is the only approved product for the treatment of Hunter syndrome, however, ERT as currently administered does not cross the Blood Brain Barrier and is therefore unable to address the unmet need in MPS II patients with CNS (neurocognition and behavior) involvement. RGX-121 is designed to deliver a healthy gene to cells in the CNS and iduronate-2-sulfatase (I2S) is then expected to be secreted by transduced cells which are then expected to cross-correct non-transduced cells by taking up the functional enzyme. This is a Phase I/II, first-in-human, multicenter, open-label, dose escalation study of RGX-121. Two, one time doses of RGX-121 will be studied in approximately 6 pediatric subjects who have severe MPS II. Safety will be the primary focus for the initial 24 weeks after treatment (primary study period) ...

Hunter syndrome (MPSII): Find the most comprehensive real-world symptom and treatment data on Hunter syndrome (MPSII) at PatientsLikeMe. 4 patients with Hunter syndrome (MPSII) experience fatigue, insomnia, depressed mood, pain, and anxious mood.

Hunter syndrome (HS) is a lysosomal storage disease caused by iduronate-2-sulfatase (IDS) deficiency and loss of ability to break down and recycle the glycosaminoglycans, heparan and dermatan sulfate, leading to impairment of cellular processes and cell death. Cell activities and functioning of intracellular organelles are controlled by the clock genes (CGs), driving the rhythmic expression of clock controlled genes (CCGs). We aimed to evaluate the expression of CGs and downstream CCGs in HS, before and after enzyme replacement treatment with IDS. The expression levels of CGs and CCGs were evaluated by a whole transcriptome analysis through Next Generation Sequencing in normal primary human fibroblasts and fibroblasts of patients affected by HS before and 24 h/144 h after IDS treatment. The time related expression of CGs after synchronization by serum shock was also evaluated by qRT-PCR before and after 24 hours of IDS treatment. In HS fibroblasts we found altered expression of several CGs and CCGs,

Accepted name: iduronate-2-sulfatase. Reaction: Hydrolysis of the 2-sulfate groups of the L-iduronate 2-sulfate units of dermatan sulfate, heparan sulfate and heparin. Other name(s): chondroitinsulfatase; idurono-2-sulfatase; iduronide-2-sulfate sulfatase; L-iduronosulfatase; L-idurono sulfate sulfatase; iduronate sulfatase; sulfo-L-iduronate sulfatase; L-iduronate 2-sulfate sulfatase; sulfoiduronate sulfohydrolase; 2-sulfo-L-iduronate 2-sulfatase; iduronate-2-sulfate sulfatase; iduronate sulfate sulfatase. Systematic name: L-iduronate-2-sulfate 2-sulfohydrolase. Links to other databases: BRENDA, EXPASY, KEGG, Metacyc, CAS registry number: 50936-59-9. References:. 1. Archer, I.M., Harper, P.S. and Wusteman, F.S. Multiple forms of iduronate 2-sulphate sulphatase in human tissues and body fluids. Biochim. Biophys. Acta 708 (1982) 134-140. [PMID: 6816283]. 2. Bach, J., Eisenberg, F., Cantz, M. and Neufeld, E.C. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc. Natl. ...

Idursulfase injection is used to treat Hunter syndrome (Mucopolysaccharidosis II, MPS II), a rare condition that is most often seen in males. Hunter syndrome is an inherited disease in which the breakdown of a certain chemical in the body (mucopolysaccharide) is defective due to the lack or absence of an enzyme called iduronate-2-sulfatase. ...

The US FDA has approved of Shire PLCs Elaprase, the first ever treatment for Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), a hereditary and potentially fatal disorder in children. Individuals afflicted with this disorder lack an enzyme called iduronate-2-sulfatase (I2S), and are unable to break down and recycle mucopolysaccharides, also known as glycosaminoglycans (GAG). When GAG accumulates in the body, symptoms of the disorder are manifested, which includes characteristic facial appearance, abnormal function of multiple organs, and in severe cases, early death.. Elaprase is a purified form of I2S manufactured by recombinant DNA technology in a human cell line. It is given as weekly infusions, a therapy that is expected to be one of the worlds most expensive medical treatments, at about $300,000 per patient per year.. ...

Background: Mucopolysaccharidosis II (MPS II) is associated with a broad spectrum of chronic and progressive, life-limiting symptoms. Idursulfase is approved for MPS II enzyme replacement therapy (ERT) in over 50 countries. This retrospective study evaluated the MPS II burden, organization of clinical care, and effects of idursulfase treatment on the disease in France. Methods: MPS II patients who had received idursulfase ERT in the French healthcare system were enrolled. In addition to clinician and patient questionnaires, the Clinical Global Impression-Improvement (CGI-I); Patient Global Impression-Improvement (PGI-I); KIDSCREEN-27, and EuroQoL-5D for adult patients scales were used to assess quality of life (QoL) and efficacy. Results: Fifty-two patients were enrolled from 5 sites in France. The majority of patients (69.2%) presented a severe MPS II phenotype with progressive neurocognitive impairment. Major impacts on QoL were apparent, with at least 1 member of the family having to reorganize

Hunter Syndrome Treatment Market - Global Hunter Syndrome Treatment Demand, Industry, Analysis, Size, Share, Trends, Growth, Estimates, Forecasts

Hunter syndrome is an inherited disorder where glycosaminoglycans (GAGs) build up in cells of the body due to a deficiency of the enzyme iduronate-2-sulfatase.

Mutations in human and/or mouse homologs are associated with this disease. Synonyms: deficiency of iduronate-2-sulphatase; Hunter syndrome; Hunters syndrome; MPS II - Hunter syndrome; Mucopolysaccharidosis, MPS-II (disorder)

The neurological impact of Hunter syndrome (MPS II) varies widely across the disease spectrum. Seizures are reported to occur in more than half of patients.

Bone deformities, hearing loss, frequent respiratory infections, cognitive impairment and chronic heart and liver disorders are symptoms suffered by infants with Hunter syndrome (also known as Mucopolysaccharidosis II). This blog follows our previous blog on associations between genotype and phenotype in very rare diseases, carried out by Shire.

44 years old American man Brian & middot; Madeleine (Brian Madeux) bearing the weight of the node of change in human history. According to the Associated Press, November 13, Madeleine with hunters syndrome at the university of California, San Francisco, Mr Benioff at childrens hospital accepted an audacious treatment: genes in the body. This is the first time in the world by editing, in vivo gene therapy of genetic diseases. a suit of casual clothes mudd pudgy, treatment on the same day, he wore a cap to keep out high convex head due to illness. Seemingly mudd just lying in bed, had a three hours of the infusion, but from the iv into mudd vein transparent liquid is recording the human no medicine can cure genetic disease against the determination. Transparent liquid contained adeno-associated virus (AAV), zinc finger nuclease (ZFN) and Madeleine was born lack normal IDS genes, they will work for some kind of unprecedented. Brian & middot; Madeleine (Brian Madeux) is undergoing treatment. ...

Fusing the necks top two vertebrae can prevent repeat strokes in children with bow hunter syndrome, a rare condition that affects a handful of U.S. pediatric patients each year, UT Southwestern researchers suggest in a recent study. The finding, published online in Childs Nervous System, offers a new way to treat these children and protect them from potentially lifelong neurological consequences.

Chris and Melissas son Case is battling Hunter Syndrome and they have come to The Doctors to share their story and spread the word about their fight to...

第一部份：第二型黏多醣儲積症IDS基因的分子遺傳研究摘 要第二黏多醣儲積症(又稱Hunter syndrome)為X染色體隱性遺傳性疾病，其起因為缺乏分解heparan sulphate及dermatan sulphate的溶小體水解酵素iduronate-2-sulfatase (IDS)。全世界有接近三百種和MPS II相關的突變被報導。本研究利用單股核酸構形多型性及DNA定序等技術，對臺灣地區10位來自不同家庭且無血緣關係的MPS II患者進行分子致因研究，結果發現5種新穎的和5種已報導過的突變。合計先前臺灣14位MPS II患者的IDS基因變異分析所發現的10種突變，於24位的臺灣MPS II患者共發現20種突變，顯示IDS基因突變的高度異質性變化。R468Q和R468W突變分別發現於3位無血緣關係的患者，其發生率共佔25.0%。利用IDS基因鄰近的DXS1123、DXS1113二核重複多型性標記，建構突變基因的單套型，結果發現無血緣關係的R468Q突變為不同的起源

GAG builds up in cells throughout the body due to a deficiency or absence of an enzyme (I2S). Buildup interferes with the way certain cells and organs in the body function and leads to serious symptoms. As the buildup of GAG continues throughout the cells of the body, signs of Hunter syndrome become more visible. Physical manifestations for some people include distinct facial features and large head. In some cases,central nervous system involvement leads to developmental delays and nervous system problems. Not all people with Hunter syndrome are affected by the disease in exactly the same way, and the rate of symptom progression varies widely. Hunter syndrome is always severe, progressive, and life-limiting ...

The recombinant fusion protein SHP631 consists of a chimeric monoclonal antibody binding to human insulin receptor and iduronate-2-sulfatase (I2S). This product is being developed as an enzyme replacement therapy to treat cognitive symptoms of Hunters syndrome. Because the current therapy (idursulfase, brand name Elaprase from Shire) cannot cross the blood-brain barrier (BBB), SHP631 is being developed to do so, enabling the presence of I2S in the brain. The enzymatic activity of this molecule is measured using the substrate 4-methyl umbelliferyl-α-L-idopyranosiduronic…. ...

Greetings Friends of the 8th Legislative District!. House Gives Initial Approval to Legislation Expanding Screenings of Newborns (HB 66). The Missouri House gave first-round approval this week to legislation that would expand screenings of newborns in Missouri to look for two more life-threatening diseases.. The bill would require that infants be screened for spinal muscular atrophy (SMA) and mucopolysaccharidosis II (MPS II), otherwise known as Hunter syndrome. Both are genetic diseases that can be fatal. Supporters say the earlier they are detected, the better outcomes can be.. The sponsor said the bill, gives families hope and it gives us a chance to save the lives of even more babies here in Missouri.. SMA results in a loss of physical strength that can include a lessened ability to walk, eat, or breathe. It is the leading genetic cause of death for infants. Hunter syndrome is caused by an enzyme deficiency that results in the buildup of harmful molecules that can affect a persons ...

At Shire, I2E is used for systematic examination of gene-disease associations. In this webinar, Madhusudan Natarajan will discuss the value of text analytics for disease severity and genotype-phenotype association, focused on Hunter Syndrome.. This rare disease, also known as Mucopolysaccharidosis II, is caused by an X-linked deficiency in iduronate-2-sulfatase. Deriving systematic annotation around patient genotypes for disease specific mutations, and correlating these to efficacy scores, immunogenicity responses etc. can offer tremendous insight into patient genotype-phenotype relationships, as well as patient genotype-outcome relationships. A meta-analysis of immunogenicity responses to administered drugs, based on patient genotype, was recently presented to, and accepted by, the European Medicines Agency. Using text analytics, these relationships have been extended to patient registries including to fulfill reporting requirements to regulatory bodies.. This webinar is based on Shires ...

The etiopathogenic mechanism that leads to closed cephalocele in Hunter disease remains unknown. In fact, the protrusion of intracranial structures could be due to an increased intracranial pressure and consequent bone remodeling, a primitive defect of skull bone formation, or both.. Increased intracranial hypertension is a relatively common and worrisome complication in MPS, as mucopolysaccharide deposition within Pacconian granulations might lead to communicating hydrocephalus, thus requiring ventricle shunt surgery. In the presence of neurologic deterioration, increased intracranial hypertension and communicating hydrocephalus are diagnosed indirectly by means of neuroradiologic signs, such as the enlargement of subarachnoid spaces, dilation of the third ventricle, and periventricular white matter signal intensity abnormalities. In our study population, we found no correlation between the presence of bone outpouching and the presence or severity of communicating hydrocephalus. This finding ...

Genetic editing has been performed in the laboratory until now. Living cells within Petri-dishes have been put under the microscope while gene editing tools such as CRISPR were used to cut, nick and replace parts of the DNA or genome that is defective with bits of DNA that is correct in its sequence. Now doctors in California have attempted to edit cells within a living person.. ...

alhamdulillah kali nie sempat bertemu dengan seorang ibu yang luar biase. ditakdirkan, anak sulungnya dihinggapi genetic disorder, mucopolysaccharidosis (sex-linked inheritance). ia disebabkan oleh kekurangan enzim iduronate sulfatase. hence, long chain sugar molecules tak dapat nak dipecahkan. komplikasi akan timbul dari pengumpulan mucopolysaccharides di organ/ bahagian badan tertentu. details, sila bace di link sni yep! [http://www.nlm.nih.gov/medlineplus/ency/article/001203.htm] ...

Purpose: To study the clinical, biochemical and molecular aspets of a family with several members affected by two X-linked diseases: mucopolysaccharidosis II and high-grade myopia. Methods: On the family study of a patient with Mucopolysaccharidosis II it was discovered several boys affected by the same disease and others by high-grade myopia. The patients with MPS II were studied with clinical, biochemical and molecular tests. The patients with myopia were submitted to a complete ophthalmologic evaluation, including retinography, Ishihara test and electroretinography. Results and Discussion: The first result found on the DNA analysis of the index case was a common mutation on exon 8 (G374G), also found in all affected boys but not on their normal brothers. The abnormality found on the affected patients was not found on the obligatory carriers, due to reasons so far not understood. In addition, on the full analysis of the IDS gene it was found a complex rearrangement, with inversion involving ...

Winner of the 2011 BMA book awards: medicine categoryIn the five decades since its first publication, Hunters Diseases of Occupations has remained the pre

Although the qualities of the show hunter are based on those of the field hunter, the modern show horse is somewhat different from its counterpart in the field. Show hunters prioritize perfection whereas field hunters reward efficiency and durability. A show hunter is supposed to make its movements look effortless; and maintain a long, low, ground-covering stride with a swinging shoulder, and a low head and neck set.[3] They are expected to never stop at a fence, cause a knockdown or a rub, and take every fence in good form and hitting every planned stride in between [3] While these characteristics are important for a field hunter, as a knockdown or a rub could result in a fall for the rider, the way of going is not as important for the field hunter as for the show hunter. The show hunter typically takes the fences at a far slower pace than the field hunter, and in far more controlled conditions. Hunters showing at indoor shows compete on flat, even surfaces over specified natural type fences ...

Looking for Mucopolysaccharide disease? Find out information about Mucopolysaccharide disease. Any of several inborn metabolic disorders involving mucopolysaccharides; the six types are MPS I, Hurlers syndrome; MPS II, Hunters syndrome; MPS III,... Explanation of Mucopolysaccharide disease

Recently, the Daily Mail released a series of private texts exchanged between Hunter Biden and other parties, which provided rather astounding insight into Hunters risqué diction. Among many words, Hunters vocabulary apparently includes various commentaries on male anatomy, alongside racial slurs.. For instance, Hunter repeatedly utilized the n-word throughout various messages with his attorney, including such gems at the following: Becaause n***a you better not be charging me Hennessy rates. Additionally, within the same message, Hunter felt compelled to send a particular image to his attorney, only to end up apologizing and informing his attorney that he is sorry for sexting [him] accidentally, and that the image in question was apparently intended for Georgia, who Hunter identifies as a friend. Even more humorously, Hunters attorney tried to respond to Hunters inquiries about finding unconditional love, mainly by informed Hunter that unconditional love is offered by the ...

Vertebral artery (VA) occlusion is a serious and potentially life-threatening occurrence. Bow hunters syndrome, a mechanical occlusion of the VA due to physiological head rotation, has been well described in the medical literature. However, mechanical VA compression due to routine flexion or extension of the neck has not been previously reported. The authors present the unique case of a woman without any history of trauma who had multiple posterior fossa strokes and was found to have dynamic occlusion of her right VA visualized via cerebral angiogram upon extension of her neck. This occlusion was attributed to instability at the occipitocervical junction in a patient with a previously unknown congenital fusion of both the occiput to C-1 and C-2 to C-3. An occiput to C-3 fusion was performed to stabilize her cervical spine and minimize the dynamic vascular compression. A postoperative angiogram showed no evidence of restricted flow with flexion or extension of the neck. This case emphasizes the ...

Hunters Point South has no obligation to monitor the Communication Services. However, Hunters Point South reserves the right to review materials posted to a Communication Service and to remove any materials in its sole discretion. Hunters Point South reserves the right to terminate your access to any or all of the Communication Services at any time without notice for any reason whatsoever.. Hunters Point South reserves the right at all times to disclose any information as necessary to satisfy any applicable law, regulation, legal process or governmental request, or to edit, refuse to post or to remove any information or materials, in whole or in part, in Hunters Point Souths sole discretion.. Always use caution when giving out any personally identifying information about yourself or your children in any Communication Service. Hunters Point South does not control or endorse the content, messages or information found in any Communication Service and, therefore, Hunters Point South ...

Hunters Point South is committed to protecting your privacy and developing technology that gives you the most powerful and safe online experience. This Statement of Privacy applies to the Hunters Point South Web site and governs data collection and usage. By using the Hunters Point South website, you consent to the data practices described in this statement.. Collection of your Personal Information. Hunters Point South collects personally identifiable information, such as your e-mail address, name, home or work address or telephone number. Hunters Point South also collects anonymous demographic information, which is not unique to you, such as your ZIP code, age, gender, preferences, interests and favorites.. There is also information about your computer hardware and software that is automatically collected by Hunters Point South. This information can include: your IP address, browser type, domain names, access times and referring Web site addresses. This information is used by Hunters ...

Hunter Bioresonance Scanner Medicomat Hunter Healthcare Diagnosis and Therapy for the Entire World. Now Everyone can be healthy with Medicomat Hunter.Healthcare Hunter Bioresonance Scanner health platform. Protect yourself and your family from viruses, bacteria, illness and pain.

Hunter x Hunter (2011): Remake of the 1999 TV series of Hunter x Hunter based on the manga by Togashi Yoshihiro.A Hunter is one who travels the world ...

Feb. 28, from 1 to 4 p.m. in Room 172 of the Natural Resources Building (NRB) in Olympia, 1111 Washington Street, off Capitol Way. Directional signs are posted in NRB parking lots. The Master Hunter program is a voluntary program sponsored by WDFW. Formerly known as the Advanced Hunter Education program, the new Master Hunter program has been redesigned to promote the highest standard of hunter ethics and help ensure continued hunting opportunity in the future. Master hunters participate in controlled hunts to eliminate problem animals that damage property and/or threaten public safety. In addition to providing certification, the program emphasizes safe, ethical, responsible, and lawful hunting practices. The deadline for enrolling in the 2009 Master Hunter program is March 31. Details on the program and enrollment procedures are available at http://wdfw.wa.gov/hunting/masterhunter/. ...

Sulfatase Modifying Factor 2/SUMF2 products available through Novus Biologicals. Browse our Sulfatase Modifying Factor 2/SUMF2 product catalog backed by our Guarantee+.

LAKE VIEW TERRACE, Calif.- Jacilyn Felton (Elvenstar, trainer) made an unforgettable debut in the USHJA National Hunter Derby at Verdugo Hills May (May 16-19), sealing the win with top scores of 90 in each round. Jacilyn had many reasons to celebrate over the weekend- she won her first hunter derby and graduated from college. This was my first time riding in a hunter derby, Jacilyn said. My plan was just to have fun without having any expectations. Ive had with my horse for about a year and hes a perfect partner. He has a background as a jumper, and I grew up doing the hunters. Weve mainly been doing equitation, so it was fun to try a hunter derby.. Jacilyn was determined to use her equitation skills to be as handy as possible. Going into the handy round, I planned to take most of the inside turns, she explained. I also took all four higher options. I tried not to rush the trot jump. It worked out well and our practice paid off. Consistency has been the key for Jacilyn who has been ...

metatron 4025 red dragon About Metatron 4025 Hunter Whats Metatron 4025 Hunter ? Simply saying, it is anadvanced Non-Invasive Diagnostic Device for physical examination & analysis system, usi...